BACKGROUND: Superparamagnetic iron oxide nanoparticles (SPIONs), due to their unique magnetic properties, have the ability to function both as magnetic resonance (MR) contrast agents, and can be used for thermotherapy. SPIONs conjugated to the heat shock protein Hsp70 that selectively binds to the CD40 receptor present on glioma cells, could be used for MR contrast enhancement of experimental C6 glioma. METHODS: The magnetic properties of the Hsp70-SPIONs were measured by NMR relaxometry method. The uptake of nanoparticles was assessed on the C6 glioma cells by confocal and electron microscopes. The tumor selectivity of Hsp70-SPIONs being intravenously administered was analyzed in the experimental model of C6 glioma in the MRI scanner. RESULTS: Hsp70-SPIONs relaxivity corresponded to the properties of negative contrast agents with a hypointensive change of resonance signal in MR imaging. A significant accumulation of the Hsp70-SPIONs but not the non-conjugated nanoparticles was observed by confocal microscopy within C6 cells. Negative contrast tumor enhancement in the T2-weighted MR images was higher in the case of Hsp70-SPIONs in comparison to non-modified SPIONs. Histological analysis of the brain sections confirmed the retention of the Hsp70-SPIONs in the glioma tumor but not in the adjacent normal brain tissues. CONCLUSION: The study demonstrated that Hsp70-SPION conjugate intravenously administered in C6 glioma model accumulated in the tumors and enhanced the contrast of their MR images.
BACKGROUND: Superparamagnetic iron oxide nanoparticles (SPIONs), due to their unique magnetic properties, have the ability to function both as magnetic resonance (MR) contrast agents, and can be used for thermotherapy. SPIONs conjugated to the heat shock protein Hsp70 that selectively binds to the CD40 receptor present on glioma cells, could be used for MR contrast enhancement of experimental C6 glioma. METHODS: The magnetic properties of the Hsp70-SPIONs were measured by NMR relaxometry method. The uptake of nanoparticles was assessed on the C6 glioma cells by confocal and electron microscopes. The tumor selectivity of Hsp70-SPIONs being intravenously administered was analyzed in the experimental model of C6 glioma in the MRI scanner. RESULTS:Hsp70-SPIONs relaxivity corresponded to the properties of negative contrast agents with a hypointensive change of resonance signal in MR imaging. A significant accumulation of the Hsp70-SPIONs but not the non-conjugated nanoparticles was observed by confocal microscopy within C6 cells. Negative contrast tumor enhancement in the T2-weighted MR images was higher in the case of Hsp70-SPIONs in comparison to non-modified SPIONs. Histological analysis of the brain sections confirmed the retention of the Hsp70-SPIONs in the glioma tumor but not in the adjacent normal brain tissues. CONCLUSION: The study demonstrated that Hsp70-SPION conjugate intravenously administered in C6 glioma model accumulated in the tumors and enhanced the contrast of their MR images.
Entities:
Keywords:
Hsp70; SPION; glioma; magnetic nanoparticles; targeted delivery
Authors: Costas G Hadjipanayis; Revaz Machaidze; Milota Kaluzova; Liya Wang; Albert J Schuette; Hongwei Chen; Xinying Wu; Hui Mao Journal: Cancer Res Date: 2010-07-20 Impact factor: 12.701
Authors: Klaus Maier-Hauff; Ronny Rothe; Regina Scholz; Uwe Gneveckow; Peter Wust; Burghard Thiesen; Annelie Feussner; Andreas von Deimling; Norbert Waldoefner; Roland Felix; Andreas Jordan Journal: J Neurooncol Date: 2006-06-14 Impact factor: 4.130
Authors: Jose-Andres C Portillo; Jennifer Van Grol; Saad Saffo; Yalitza Lopez Corcino; Myriam Rodriguez; Barbara A Fox; David J Bzik; Nicole L Ward; George R Dubyak; Roxana E Rojas; Zahra Toosi; Carlos S Subauste Journal: Infect Immun Date: 2019-07-23 Impact factor: 3.441
Authors: Georgios P Skandalakis; Daniel R Rivera; Caroline D Rizea; Alexandros Bouras; Joe Gerald Jesu Raj; Dominique Bozec; Constantinos G Hadjipanayis Journal: Int J Hyperthermia Date: 2020-07 Impact factor: 3.914
Authors: Maxim A Shevtsov; Boris P Nikolaev; Ludmila Y Yakovleva; Anatolii V Dobrodumov; Alexander V Zhakhov; Anastasiy L Mikhrina; Emil Pitkin; Marina A Parr; Valerii I Rolich; Andrei S Simbircev; Alexander M Ischenko Journal: Neoplasia Date: 2015-01 Impact factor: 5.715
Authors: Maxim A Shevtsov; Boris P Nikolaev; Ludmila Y Yakovleva; Anatolii V Dobrodumov; Anastasiy S Dayneko; Alexey A Shmonin; Timur D Vlasov; Elena V Melnikova; Alexander D Vilisov; Irina V Guzhova; Alexander M Ischenko; Anastasiya L Mikhrina; Oleg V Galibin; Igor V Yakovenko; Boris A Margulis Journal: Drug Des Devel Ther Date: 2014-05-28 Impact factor: 4.162
Authors: Maxim A Shevtsov; Elena Y Komarova; Darya A Meshalkina; Natalia V Bychkova; Nikolai D Aksenov; Sergey V Abkin; Boris A Margulis; Irina V Guzhova Journal: Oncotarget Date: 2014-05-30
Authors: M A Shevtsov; M A Parr; V A Ryzhov; E G Zemtsova; A Yu Arbenin; A N Ponomareva; V M Smirnov; G Multhoff Journal: Sci Rep Date: 2016-07-08 Impact factor: 4.379
Authors: Maxim A Shevtsov; Alexander V Kim; Konstantin A Samochernych; Irina V Romanova; Boris A Margulis; Irina V Guzhova; Igor V Yakovenko; Alexander M Ischenko; William A Khachatryan Journal: Onco Targets Ther Date: 2014-06-18 Impact factor: 4.147